Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. (Record no. 270)

MARC details
000 -LEADER
fixed length control field 03484nam a22003497a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221018s20222022 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0028-4793
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1056/NEJMoa2204961 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 36121045
245 ## - TITLE STATEMENT
Title Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.
251 ## - Source
Source New England Journal of Medicine. 2022 Sep 17
252 ## - Abbreviated Source
Abbreviated source N Engl J Med. 2022 Sep 17
253 ## - Journal Name
Journal name The New England journal of medicine
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Sep 17
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status aheadofprint
266 ## - Date added to catalog
Date added to catalog 2022-10-20
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke.
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: Among patients with aortic stenosis undergoing transfemoral TAVR, the use of CEP did not have a significant effect on the incidence of periprocedural stroke, but on the basis of the 95% confidence interval around this outcome, the results may not rule out a benefit of CEP during TAVR. (Funded by Boston Scientific; PROTECTED TAVR ClinicalTrials.gov number, NCT04149535.). Copyright © 2022 Massachusetts Medical Society.
520 ## - SUMMARY, ETC.
Abstract METHODS: We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group). The primary end point was stroke within 72 hours after TAVR or before discharge (whichever came first) in the intention-to-treat population. Disabling stroke, death, transient ischemic attack, delirium, major or minor vascular complications at the CEP access site, and acute kidney injury were also assessed. A neurology professional examined all the patients at baseline and after TAVR.
520 ## - SUMMARY, ETC.
Abstract RESULTS: A total of 3000 patients across North America, Europe, and Australia underwent randomization; 1501 were assigned to the CEP group and 1499 to the control group. A CEP device was successfully deployed in 1406 of the 1489 patients (94.4%) in whom an attempt was made. The incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group (2.3% vs. 2.9%; difference, -0.6 percentage points; 95% confidence interval, -1.7 to 0.5; P = 0.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and in 1.3% of those in the control group. There were no substantial differences between the CEP group and the control group in the percentage of patients who died (0.5% vs. 0.3%); had a stroke, a transient ischemic attack, or delirium (3.1% vs. 3.7%); or had acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Heart & Vascular Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Satler, Lowell
790 ## - Authors
All authors Abdel-Wahab M, Allocco DJ, Baron SJ, Gooley R, Harrington K, Horr S, Kapadia SR, Karha J, Kodali S, Krishnaswamy A, Leon M, Linke A, Makkar R, Massberg S, Meredith IT, Messe SR, Modolo R, Pocock S, PROTECTED TAVR Investigators, Rottbauer W, Satler L, Seeger J, Sondergaard L, Stoler RC, Thourani VH, Waggoner T
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1056/NEJMoa2204961">https://dx.doi.org/10.1056/NEJMoa2204961</a>
Public note https://dx.doi.org/10.1056/NEJMoa2204961
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 10/20/2022   36121045 36121045 10/20/2022 10/20/2022 Journal Article

Powered by Koha